Bellicum's cell therapy collaboration sends share price on the up

1 November 2016
2019_biotech_test_vial_discovery_big

The share price of USA-based Bellicum Pharmaceuticals (Nasdaq:BLCM) increased by 2.5% to $16.98 on Tuesday morning after its expanded cell therapy collaboration with a European pediatric research center and hospital was announced.

Bellicum, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan-inherited blood disorders, is to develop CAR T and TCR product candidates that incorporate its control switch technology, CaspaCIDe, in the collaboration with Italy’s Ospedale Pediatrico Bambino Gesù (OPBG).

"This partnership could benefit children and adults with life-threatening cancers throughout the world"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology